Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 4/20 | 0.66 |
| ▸ | FFAR2 | O15552 | 5/20 | 0.50 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.46 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9107973 | 0.85 | GCK (0.79) | GCKFFAR2HSPA5HSPA2MEN1 | |
| SCHEMBL9104134 | 0.84 | GCK (0.55) | GCK | |
| SCHEMBL9106852 | 0.83 | GCK (0.61) | GCKFFAR2HSPA5HSPA2MEN1 | |
| SCHEMBL9103861 | 0.83 | GCK (0.66) | GCKFFAR2HSPA5HSPA2MEN1 | |
| SCHEMBL9105927 | 0.82 | GCK (0.45) | GCKFFAR2MEN1KMT2ALMNA | |
| SCHEMBL9103438 | 0.82 | GCK (0.64) | GCKFFAR2HSPA5HSPA2MEN1 | |
| SCHEMBL9106900 | 0.81 | KDM4E (0.44) | GCKFFAR2MEN1KMT2ANPC1 | |
| SCHEMBL9908079 | 0.81 | KDM4E (0.44) | GCKFFAR2MEN1KMT2ANPC1 | |
| SCHEMBL1317245 | 0.79 | GCK (1.00) | GCKFFAR2HSPA5HSPA2MEN1 | |
| SCHEMBL9106076 | 0.79 | GCK (0.66) | GCKFFAR2HSPA5HSPA2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142705-A1 | ISATIN AND OXINDOLE COMPOUNDS | KESTER ROBERT FRANCIS (US) | 2012-06-07 | — | — | US | claimed |
| US-20120142705-A1 | ISATIN AND OXINDOLE COMPOUNDS | KESTER ROBERT FRANCIS (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142705-A1 | ISATIN AND OXINDOLE COMPOUNDS | KESTER ROBERT FRANCIS (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142705-A1 | ISATIN AND OXINDOLE COMPOUNDS | KESTER ROBERT FRANCIS (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142705-A1 | ISATIN AND OXINDOLE COMPOUNDS | GPR119, INSR, OAT | GCK 488/4885FFAR2 627/4885HSPA5 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.